Rakuten Medical Secures AMED Funding for RM-0256 Anti-PD-L1 Antibody IR700 Conjugate Rakuten Medical's innovative RM-0256, an anti-PD-L1 antibody conjugate, has been chosen for AMED funding, paving the way for advanced cancer therapies.

Rakuten Medical Secures AMED Funding for RM-0256 Anti-PD-L1 Antibody IR700 Conjugate #Japan #San_Diego #Rakuten_Medical #RM-0256 #AMED_Funding